Finasteride

證據等級: L5

預測適應症: 10 個

Finasteride: From Benign Prostatic Hyperplasia to Prostate Calculus

One-Sentence Summary

Finasteride is a 5α-reductase type 2 inhibitor whose established use (per the mechanistic notes in this evidence pack) is benign prostatic hyperplasia (BPH) and androgenetic alopecia. Of the 10 TxGNN-predicted indications supplied, 9 — including the top-ranked “Ambras type hypertrichosis” — have no supporting evidence and mechanistically implausible or opposite-direction rationale, and are excluded from further evaluation here. The one candidate worth documenting is Prostate Calculus, supported by 0 clinical trials and 10 publications (mostly observational/cohort studies, no direct RCTs), giving weak but plausible indirect evidence via the drug’s known effect on prostate volume and urinary flow.

Quick Overview

Item	Content
Original Indication	Not present in structured licence data (no ARTG entries on file). Per the evidence pack’s mechanistic notes, finasteride’s existing indications are BPH and androgenetic alopecia.
Predicted New Indication	Prostate Calculus
TxGNN Prediction Score	98.60% (rank 13,782 of all candidates — a lower-confidence tier than the top-ranked but implausible predictions)
Evidence Level	L3
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

A formal, DrugBank-verified mechanism of action record is not currently available for this drug (data gap — high severity). Based on the mechanistic notes captured in this evidence pack, finasteride is a type II 5α-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), and this pathway underlies its established use in reducing prostate volume and improving lower urinary tract symptoms in BPH.

Prostate calculi frequently co-occur with BPH, chronic prostatic inflammation and urinary retention/stasis, which are recognised risk factors for stone formation. The proposed link is therefore indirect: by shrinking prostate volume and improving urinary flow, finasteride could theoretically reduce the conditions that favour calculus formation or progression — not that it dissolves or directly treats existing stones.

Importantly, none of the 10 supporting publications directly studied finasteride as a treatment for prostate calculus; they address BPH management, bladder-stone/BPH surgical outcomes, and lower urinary tract symptoms more broadly. The mechanistic link is plausible but unproven, which is reflected in the L3 evidence level (observational/review evidence only, no direct trial).

The other 9 TxGNN-ranked candidates in this evidence pack (including the highest-scoring “Ambras type hypertrichosis,” at 99.99%) were reviewed and found to have no clinical trials, no literature, and/or mechanistically opposite or unrelated rationale — most likely knowledge-graph embedding noise rather than genuine repurposing signal. They are not carried forward in this report.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40658396	2025	Review	JAMA	Lower urinary tract symptoms in men, including BPH, can progress to complications such as bladder calculi if untreated.
34807286	2022	Cohort (RCT-style comparative)	World J Urol	Combined TURP + cystolitholapaxy gave better outcomes than stone removal plus medical BPH therapy in patients with concurrent bladder stones and BPH.
12137828	2002	Cohort/Retrospective	Urology	Men with bladder calculi and BPH who skipped TURP after endoscopic stone removal were followed to assess non-surgical (medical) BPH management outcomes.
21296391	2011	Cohort	Urology	Compared endoscopic stone removal alone vs. with TURP, questioning whether prostate surgery is a necessary adjunct to stone treatment.
7541333	1995	Review	Disease-a-Month	Overview of BPH pathophysiology (DHT-driven) and evaluation, foundational context for finasteride’s mechanism.
11074197	2000	Review	Urology	Discusses preventive care paradigms in urology, including risk-reduction strategies for BPH-related complications.
8545348	1995	Review	Presse Médicale	Medical management of BPH, noting bladder calculi as a historical indication for surgery rather than medical therapy.
21789983	2011	Review	The Practitioner	General review of BPH/LUTS management approaches in primary care.
12224431	2002	Review	Actas Urológicas Españolas	Review of BPH treatment options, medical and surgical, with future outlook.
20062548	2009	Case Report	Cases Journal	Case report on prostate changes after spinal cord injury; tangential relevance to prostate pathology generally.

Australia Market Information

No ARTG entries are recorded for this product in the current evidence pack (market status: not marketed, 0 licences on file).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. (No structured warnings, contraindications, or drug interaction data were retrievable for this evidence pack — this is flagged as a blocking data gap that must be resolved before safety assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale (BPH → reduced prostate volume/urinary stasis → lower calculus risk) is biologically plausible but entirely indirect — no clinical trial or study has directly tested finasteride for prostate calculus, and the product currently has no ARTG registration. A blocking data gap on TGA Product Information (warnings/contraindications) also prevents any preliminary safety assessment.

To proceed, the following is needed:

TGA-approved Product Information (warnings, contraindications) — currently a blocking gap
DrugBank-verified mechanism of action to replace the rationale-derived MOA used in this report
A direct observational study or trial examining finasteride’s effect on prostate calculus incidence/progression (current evidence only addresses BPH/LUTS management generally)
Confirmation of current Australian market/ARTG status, given finasteride is a long-established molecule elsewhere
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.